35 completed, 2 terminated, 1 unknown. 38 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 38 | Completed 35, Terminated 2, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
Follow Rosacea: new trials by email Literature Review of Rosacea trials Research Report on Rosacea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2) DFD-29, Doxycycline, Placebo - Papulopustular Rosacea | Phase 3 | Completed | Journey Medical Corporation | 330 | 2022-03-29 | 2024-12-03 |
| A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea. DFD-29, Doxycycline, Placebo - Papulopustular Rosacea | Phase 3 | Completed | Journey Medical Corporation | 323 | 2022-03-14 | 2024-12-03 |
| A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream" Oxymetazoline Hydrochloride, Rhofade Cream, 1%, Placebo - Rosacea | Phase 3 | Completed | Actavis Inc. | 1105 | 2019-04-15 | 2021-06-23 |
| A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea S5G4T-1 - Papulopustular Rosacea | Phase 3 | Terminated | Sol-Gel Technologies, Ltd. | 547 | 2018-09-12 | 2021-12-15 |
| A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea S5G4T-1, S5G4T-2 - Papulopustular Rosacea | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 372 | 2018-06-21 | 2021-12-15 |
| A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea S5G4T-1, S5G4T-2 - Papulopustular Rosacea | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 361 | 2018-06-18 | 2021-12-14 |
| An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea Oxymetazoline - Rosacea, Erythema | Phase 3 | Completed | Padagis LLC | 50 | 2017-10-18 | 2021-11-08 |
| A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea FMX103 1.5% - Papulopustular Rosacea | Phase 3 | Completed | Vyne Therapeutics Inc. | 504 | 2017-09-05 | 2022-01-18 |
| Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face Azelaic acid foam, Azelaic acid foam - Placebo - Rosacea | Phase 3 | Completed | Padagis LLC | 667 | 2016-11-01 | 2021-11-08 |
| A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea Generic Azelaic Acid Foam, Finacea® (Azelaic Acid) Foam, Vehicle Foam - Rosacea | Phase 3 | Completed | Actavis Inc. | 924 | 2016-07-19 | 2019-07-31 |
| Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea Ivermectin, Ivermectin (reference), Placebo - Rosacea | Phase 3 | Completed | Padagis LLC | 486 | 2016-05-01 | 2021-11-02 |
| Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle CLS001 (Omiganan), Vehicle - Rosacea | Phase 3 | Completed | Maruho Co., Ltd. | 463 | 2015-12-01 | 2022-08-02 |
| Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle CLS001 (Omiganan), Vehicle - Rosacea | Phase 3 | Completed | Maruho Co., Ltd. | 263 | 2015-10-01 | 2022-08-02 |
| Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel Omiganan - Rosacea | Phase 3 | Completed | Maruho Co., Ltd. | 307 | 2015-10-01 | 2022-07-19 |
| Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea Brimonidine Topical Gel, 0.33 percent (Perrigo), Brimonidine Topical Gel, 0.33 percent (Reference), Placebo gel - Rosacea | Phase 3 | Completed | Padagis LLC | 552 | 2015-03-01 | 2021-10-22 |
| A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%, Placebo Gel - Papulopustular Rosacea, Erythematotelangiectatic Rosacea | Phase 3 | Completed | bioRASI, LLC | 963 | 2015-02-01 | 2020-09-03 |
| Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea Brimonidine, placebo - Rosacea | Phase 3 | Completed | Actavis Inc. | 462 | 2014-07-01 | 2020-01-14 |
| Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea Oxymetazoline HCL Cream 1.0%, Vehicle to Oxymetazoline HCL Cream - Erythema, Rosacea | Phase 3 | Completed | Allergan | 445 | 2014-06-01 | 2019-11-18 |
| Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea AGN-199201, Vehicle to AGN-199201 - Erythema, Rosacea | Phase 3 | Completed | Allergan | 440 | 2014-05-01 | 2019-11-18 |
| A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea Oxymetazoline HCL Cream 1.0% - Erythema, Rosacea | Phase 3 | Completed | Allergan | 440 | 2014-04-01 | 2019-11-18 |
Showing 20 of 38. Sign in to see all of them.
Erythema (6)
Skin Diseases (38) · Skin and Connective Tissue Diseases (38) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Skin Manifestations (6)
azelaic acid (5) · Doxycycline (4) · Gels (4) · Omiganan (3) · Ivermectin (2) · Metronidazole (2) · Oxymetazoline (2) · Atralin Gel (1) · Brimonidine Tartrate (1) · Drugs, Generic (1) · Sunscreening Agents (1) · Tretinoin (1) · clindamycin phosphate (1) · clindamycin, tretinoin drug combination (1)
Galderma R&D (9) · Actavis Inc. (4) · Padagis LLC (4) · Allergan (3) · Maruho Co., Ltd. (3) · Sol-Gel Technologies, Ltd. (3) · CollaGenex Pharmaceuticals (2) · Journey Medical Corporation (2) · Fougera Pharmaceuticals Inc. (1) · LEO Pharma (1) · Lisa E. Maier (1) · Massachusetts General Hospital (1) · Rabin Medical Center (1) · Vyne Therapeutics Inc. (1) · Wake Forest University (1)
United States (30) · Canada (7) · France (5) · Germany (5) · Sweden (5) · United Kingdom (5) · Australia (3) · Netherlands (3) · New Zealand (3) · Russia (2) · Bulgaria (1) · Czechia (1) · Hungary (1) · Israel (1) · Poland (1)
Angela Moore, MD (2) · Michael Graeber, M.D. (2) · Michael Graeber, MD (2) · Srinivas R Sidgiddi, M.D. (2) · Alan Fleischer, MD (1) · Alexa Kimball, MD, MPH (1) · Amanda Tauscher, MD (1) · Andrew Pollack, MD (1) · Angela C Kaplan (1) · Ava Shamban, MD (1) · Catherine Pointon, MD (1) · Charles Lynde, MD (1) · Daniel Stewart, DO (1)
PMID 37636253, PMID 40042869, PMID 22395584, PMID 26244354, PMID 26416154, PMID 36781451, PMID 37636251